期刊文献+

非诺贝特胶囊剂及家犬体内生物利用度 被引量:1

Fenofibrate capsules and its bioavailability on dogs
下载PDF
导出
摘要 目的采用纳米分散技术制备非诺贝特胶囊剂,以提高其溶出度及生物利用度。方法用反溶剂沉淀法和高压匀质法制备非诺贝特纳米混悬剂,并通过喷雾干燥将其固化以制备胶囊剂,用差示扫描量热法(differential scanning calorimetry,DSC)和X-射线粉末衍射分析表征药物在胶囊剂中的存在状态,并测定药物的溶出度及家犬体内的生物利用度。结果非诺贝特以纳米晶体状态分散于胶囊剂中,自制胶囊溶出度为国产胶囊的3倍,相对生物利用度为国产胶囊的(274.5±15.6)%。结论自制非诺贝特胶囊剂可以通过增加非诺贝特的分散度来提高药物的溶出度与生物利用度。 Objective To prepare fenofibrate capsules using the nanosuspension technique for dissolution improvement and the bioavailability enhancement. Methods The fenofibrate nanosuspension was prepared using the method of anti-solvent precipitation technology and high pressure homogenization, then the dispersion was solidified by the method of spray drying to obtain fenofibrate capsules. The state of fenofibrate in nanosuspension was determined by using DSC and X-ray diffraction. The dissolution in vitro and bioavailability on dogs were also measured. Results Fenofibrate of preparation was existed in the forms of crystal. The dissolution of fenofibrate nanosuspension was three times higher than that of common commercial preparation. The bioavailability of self-made fenofibrate capsules was (274. 5 ± 15.6)% of common capsules. Conclusions Fenofibrate nanosuspension can improve dissolution and bioavailability with dispersibility increment.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2011年第11期912-916,共5页 Journal of Shenyang Pharmaceutical University
基金 国家重点基础研究发展计划(973计划)2009CB930300
关键词 非诺贝特 纳米混悬剂 喷雾干燥 胶囊剂 溶出度 相对生物利用度 fenofibrate nanosuspension spray drying capsules dissolution bioavailability
  • 相关文献

参考文献8

  • 1LIPINSKI C A. Drug like properties and the causes of poor solubility and poorpermeability [ J ]. J Pharmacol Toxicol Methods ,2000,44( 1 ) :235 - 249.
  • 2PINNAMANENI S, DAS NG, DAA SK. Formulation approaches for orally administered poorly soluble drugs [ J ]. Pharmazie,2002,57 (5) : 291 - 300.
  • 3熊若兰,陆伟根.纳米混悬剂研究进展[J].世界临床药物,2007,28(2):117-121. 被引量:14
  • 4RAO G C, KUMAR M S,MATHIVANAN N, et al. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems [ J ]. Phar-mazie, 2004,59(1) :5 -9.
  • 5PATRAVALE V B, DATE A A, KULKARNI R M. Nanosuspensions: a promising drug delivery strategy[J ]. J Pharm Pharmcol,2004,56 (7) : 827 - 840,.
  • 6DUCHENE D, PONCHEL G. Bioadhesion of solid oral dosage form, why and how [ J ]. Eur J Pharm Biop- harm, 1997,44( 1 ) :15 -23.
  • 7范国荣,林梅,张正行,安登魁.人血浆中非诺贝特活性代谢物非诺贝酸的高效液相色谱法测定[J].药物分析杂志,2000,20(4):231-234. 被引量:11
  • 8HUANG Qiao-ping, WANG Jie-xin, ZHANG Zhi- bing,Preparation of ultrafine fenofibrate powder by so- lidification process from emulsion [ J ]. International Journal of Pharmaceutics ,2009,368 :160 - 164.

二级参考文献30

  • 1滕小玉,管忠震,姚志文,刘冬耕,周宁宁,罗汉钰,Michael Hawkins,Patrick Soon-Shiong.晚期实体癌患者对不含聚氧乙烯蓖麻油注射用紫杉醇白蛋白纳米粒悬浮液的临床耐受性研究[J].癌症,2004,23(z1):1431-1436. 被引量:39
  • 2郑颉,药物分析杂志,1988年,8卷,2期,89页
  • 3Willems L;van der Geest R;de Beule K.Itraconazole oral solution and intravenous formulations:a review of pharmacokinetics and pharmacodynamics[J],2001(03).
  • 4内尔·P·代塞;帕奇克·苏-雄什落莫·马格达西;大卫·C·沙哈地万.药剂的新制剂及其制备和应用方法,2004.
  • 5Jacobs C;Kayser O;Müller RH.Nanosuspensions as a new approach for the formulation for thepoorly soluble drug tarazepide[J],2000(02).
  • 6Krause KP;Kayser O;Mader K.Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation[J],2000(02).
  • 7Patravale VB;Date AA;Kulkarni RM.Nanosuspensions:a promising drug delivery strategy[J],2004(07).
  • 8Kreft WK;Steiger B;Beussink D.The pharmacokeinetics of nebulized nanocrystal budesonide suspension in heslthy volunteers,2004(01).
  • 9Alyautdin RN;Petrov VE;Langer K.The delivery of Ioperamide to the brain by using polybutyl cyanoacrylate nanoparticles,1998(01).
  • 10Peters K;Leitzke S;Diederichs JE.Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection[J],2000(01).

共引文献23

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部